

Freedom of Information Act Request

I am writing to request information under the Freedom of Information Act 2000.

Q1. How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 – December 2025)?

- Ocrevus (ocrelizumab) IV (300mg/30ml)
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
- Kesimpta (ofatumumab)
- Briumvi (ublituximab)
- Mavenclad (cladribine)
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
- Natalizumab (Tysabri and Tyruko)

DBTH holds the information on the subject you have requested. However, I advise you that we will not be able to answer your request without exceeding the appropriate limit. This is because our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

. Section 12 of the Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit, We have estimated that it would take more than 18 hours to carry out a manual search to locate, retrieve, and extract all the information you have requested. In this situation the associated cost would therefore exceed the appropriate fee limit of £450 set out under Freedom of Information & Data Protection (Appropriate Limit and Fees) Regulations 2007.

The fee limit specified in regulations for NHS trusts represents the cost of one person spending 2½ working days at a rate of £25 per hour determining whether the Trust holds the information sought and then locating, retrieving and extracting that information.

Q1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 – December 2025?) **N/A**

- Ocrevus (ocrelizumab) IV (300mg/30ml)
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
- Kesimpta (ofatumumab)

Our Ref: 29
January 2026

- Briumvi (ublituximab)
- Mavenclad (cladribine)
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
- Natalizumab (Tysabri and Tyruko)

Q2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 – December 2025)?

The Trust does not hold information that allows it to identify the number of patients who received a *first-ever* diagnosis of Multiple Sclerosis during the requested period.

Patients may receive an initial diagnosis of Multiple Sclerosis:

- In primary care (GP practices),
- At another NHS Trust, or
- Through another healthcare provider,

This information is not consistently recorded or shared in a way that enables the Trust to determine whether a diagnosis made or recorded during an admission represents the patient's first diagnosis overall. The Trust therefore confirms that information relating to *true first diagnoses* of Multiple Sclerosis is not held for the purposes of the Freedom of Information Act.

Q2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?

- Ocrevus (ocrelizumab) IV (300mg/30ml)
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
- Kesimpta (ofatumumab)
- Briumvi (ublituximab)
- Mavenclad (cladribine)
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
- Natalizumab (Tysabri and Tyruko)

DBTH holds the information on the subject you have requested. However, I advise you that we will not be able to answer your request without exceeding the appropriate limit. This is because our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Our Ref: 29
January 2026

. Section 12 of the Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit, We have estimated that it would take more than 18 hours to carry out a manual search to locate, retrieve, and extract all the information you have requested. In this situation the associated cost would therefore exceed the appropriate fee limit of £450 set out under Freedom of Information & Data Protection (Appropriate Limit and Fees) Regulations 2007.

The fee limit specified in regulations for NHS trusts represents the cost of one person spending 2½ working days at a rate of £25 per hour determining whether the Trust holds the information sought and then locating, retrieving and extracting that information.

If you are not satisfied with the handling of your request, you have the right to request an internal review. Requests for an internal review should be submitted within 40 working days from the date of this response, and should be addressed to d.wraith@nhs.net.

If you remain dissatisfied after the internal review, you have the right to appeal to the Information Commissioner's Office (ICO). The ICO can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
Website: <https://ico.org.uk/make-a-complaint/>

Our Ref: 29
January 2026